Skip to main content
Premium Trial:

Request an Annual Quote

German Gov t Sets Aside 135M Euros for 180 Additional NGRN Projects

NEW YORK, Dec. 7 (GenomeWeb News) - Germany's Federal Ministry for Education and Research has set aside an additional135 million ($181.3 million) to fund more than 180 research projects in the second three-year phase of the interdisciplinary National Genome Research Network, according to a news report.


The NGFN attracted180 million of FMER funding in its first phase. "Headlining projects from the first phase are set to continue," according to the website Research Research.


Research Minister Edelgard Bulmahn said that the new projects will focus on "major diseases," the report said. He added that this second phase would "increase Germany's international competitiveness in the life sciences," according to Research Research.

The first phase helped spur more than 80 patent applications, 1,500 scientific publications, and more than 90 "product ideas" in collaboration with industry, the report said.

The NGFN network of clinical scientists and molecular biologists will concentrate on heart and circulatory diseases, cancer, infectious diseases, environmental epidemiology, and central nervous system diseases. Around 300 research groups from 30 universities are involved in the second phase of NGFN. These include 10 Max Planck institutes, four Helmholtz centers, five Leibniz institutes, nine biotechnology companies, and the European Molecular Biology Laboratory, the report said.

According to Research Research, projects will be divided into three categories: Disease-related genome networks, which will study "causes, prevention, and treatment" of major diseases; systematic-methodological platforms, which will "concentrate on applying technology to human genome research; and explorative projects, which will "develop innovative ideas and new research directions."


The NGFN was created in 2001 to "promote interdisciplinary cooperation between experts studying the genetic basis of disease," the report said.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.